Pharmacokinetic-pharmacodynamic analysis of vismodegib in patients with basal cell carcinoma (the OPTIVISMO study)
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
WHAT IS KNOWN AND OBJECTIVE
Vismodegib is indicated in patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC when surgery or radiotherapy are not appropriate. The significant efficacy of vismodegib in responding patients and lack of therapeutic alternatives are counterbalanced by intolerance and severe adverse events (AEs), leading to discontinuation in 30% of patients. We aimed to evaluate the relationship between vismodegib pharmacokinetics (PK) and occurrence of AEs, and to investigate the association between concentrations and response in terms of efficacy.
RESULTS
Mean of trough vismodegib plasma concentrations ranged from 3.9 mg/L to 30 mg/L per patient, with an overall mean of 11.8 (± 5) mg/L. A high correlation between total vismodegib and alpha-1 acid glycoprotein (AAG) levels was observed (Spearman’s ρ = 0.6733, p-value =1.662e-12). Inter-individual variability was significant (CV% of 42%).
Patients with stable and progressive disease had a significantly higher median vismodegib plasma concentration than those with partial and complete response (p = 0.03).
Tumor volume ranged from 0 to 12 292 135 mm 3 in our cohort. Mean tumor volume slope was -1187.97 (± 9734).
WHAT IS KNEW AND CONCLUSION
We explored PK/pharmacodynamic (PD) relationships of vismodegib in patients with BCC. This is the first study which reported PK data obtained in BCC patients treated with vismodegib in a real-life clinical practice.
Our study confirmed the strong influence of AAG levels on vismodegib protein binding. Concerning the PK/PD relationship evaluation, we notably observed that patients with the lowest plasma concentrations respond best to treatment. Our mathematical estimation of tumor volume showed that between the beginning and the end of the study, tumor growth was positively correlated to vismodegib levels, which was in line with the correlation observed for efficacy/safety data.
